Completed PHASE4 INTERVENTIONAL 2-arm NCT01461668

Retapamulin for Reducing MRSA Nasal Carriage

Sponsor: Agency for Healthcare Research and Quality (AHRQ)

Conditions Methicillin-Resistant Staphylococcus Aureus

Updated 10 times since 2017 Last updated: Mar 29, 2018 Started: Jul 31, 2012 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01461668, this PHASE4 trial focuses on Methicillin-Resistant Staphylococcus Aureus and remains completed. Sponsored by Agency for Healthcare Research and Quality (AHRQ), it has been updated 10 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Dec 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 5 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
May 2018 — Jun 2018 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Feb 2017 — May 2018 [monthly]

Active Not Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE4

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Agency for Healthcare Research and Quality (AHRQ)
University of California, Irvine

Data source: University of California, Irvine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Irvine, United States